197 related articles for article (PubMed ID: 24761480)
21. [Cost saving program instead of optimizing therapy: disease mismanagement in diabetes mellitus? (interview by Dr. med. Jochen Aumiller)].
Rett K
MMW Fortschr Med; 2005 Jun; 147(22):15. PubMed ID: 15977626
[No Abstract] [Full Text] [Related]
22. [Long-acting insulins in the treatment of type 2 diabetes: a hard choice].
Liebl A
MMW Fortschr Med; 2015 Apr; 157(7):65-8. PubMed ID: 26012462
[No Abstract] [Full Text] [Related]
23. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
24. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
25. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.
Hirsch IB; Schneider D; King A; Polonsky WH; Reid TS; Shubrook J; Verderese CA; Wallace J; Riddle MC
Postgrad Med; 2014 May; 126(3):135-44. PubMed ID: 24918799
[TBL] [Abstract][Full Text] [Related]
26. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Van Gaal LF; Gutkin SW; Nauck MA
Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
[TBL] [Abstract][Full Text] [Related]
27. [Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].
Ando Y
Nihon Rinsho; 2013 Nov; 71(11):1993-8. PubMed ID: 24397172
[TBL] [Abstract][Full Text] [Related]
28. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
[No Abstract] [Full Text] [Related]
29. Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination.
Moghissi ES
J Am Osteopath Assoc; 2014 May; 114(5 Suppl 2):S22-9. PubMed ID: 24769505
[TBL] [Abstract][Full Text] [Related]
30. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
Holst JJ; Seino Y
Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
[No Abstract] [Full Text] [Related]
31. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Lüdemann J
MMW Fortschr Med; 2011 Jul; 153 Suppl 2():56-63. PubMed ID: 23964469
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
34. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
[No Abstract] [Full Text] [Related]
35. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?
Shehadeh N; Daich E; Zuckerman-Levin N
Pediatr Endocrinol Rev; 2014 Mar; 11(3):324-7. PubMed ID: 24716398
[TBL] [Abstract][Full Text] [Related]
36. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
[TBL] [Abstract][Full Text] [Related]
37. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
[TBL] [Abstract][Full Text] [Related]
38. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
39. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia.
Bandsma RH; Lewis GF
Atherosclerosis; 2010 Sep; 212(1):40-1. PubMed ID: 20638063
[No Abstract] [Full Text] [Related]
40. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
